AT290375T - Use of a means to reduce the risk of cardiovascular diseases - Google Patents

Use of a means to reduce the risk of cardiovascular diseases

Info

Publication number
AT290375T
AT290375T AT98917992T AT98917992T AT290375T AT 290375 T AT290375 T AT 290375T AT 98917992 T AT98917992 T AT 98917992T AT 98917992 T AT98917992 T AT 98917992T AT 290375 T AT290375 T AT 290375T
Authority
AT
Austria
Prior art keywords
risk
reduce
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
AT98917992T
Other languages
German (de)
Inventor
Paul Ridker
Charles H Hennekens
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US4195097P priority Critical
Priority to US4303997P priority
Priority to US7089498P priority
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Priority to PCT/US1998/006613 priority patent/WO1998043630A1/en
Publication of AT290375T publication Critical patent/AT290375T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27366025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT290375(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
AT98917992T 1997-04-02 1998-04-02 Use of a means to reduce the risk of cardiovascular diseases AT290375T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US4195097P true 1997-04-02 1997-04-02
US4303997P true 1997-04-02 1997-04-02
US7089498P true 1998-01-09 1998-01-09
PCT/US1998/006613 WO1998043630A1 (en) 1997-04-02 1998-04-02 Means of ascertaining an individual's risk profile for atherosclerotic disease

Publications (1)

Publication Number Publication Date
AT290375T true AT290375T (en) 2005-03-15

Family

ID=27366025

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98917992T AT290375T (en) 1997-04-02 1998-04-02 Use of a means to reduce the risk of cardiovascular diseases
AT04010424T AT530180T (en) 1997-04-02 1998-04-02 Method for determining the individual risk profiles of atherosclerotic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04010424T AT530180T (en) 1997-04-02 1998-04-02 Method for determining the individual risk profiles of atherosclerotic diseases

Country Status (12)

Country Link
US (1) US6040147A (en)
EP (4) EP2305235A1 (en)
JP (4) JP3805381B2 (en)
AT (2) AT290375T (en)
AU (1) AU7100898A (en)
CA (1) CA2285091A1 (en)
CY (1) CY1112261T1 (en)
DE (1) DE69829293T2 (en)
DK (2) DK1493439T3 (en)
ES (2) ES2239801T3 (en)
PT (2) PT1493439E (en)
WO (1) WO1998043630A1 (en)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
JP2003508453A (en) * 1999-08-31 2003-03-04 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerosis
EP1520590A1 (en) * 1999-08-31 2005-04-06 The Brigham and Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1767222A1 (en) * 1999-08-31 2007-03-28 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
US7030152B1 (en) * 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
WO2000013021A1 (en) * 1998-08-27 2000-03-09 Mayo Foundation For Medical Education And Research Methods and materials for diagnosing unstable angina
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
DE19847690A1 (en) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
AT282208T (en) * 1999-02-04 2004-11-15 Bio Merieux Inc Method and device for predicting haemostatic functional failure in patient samples
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US7179612B2 (en) * 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU1802602A (en) 2000-11-09 2002-05-21 Brigham & Womens Hospital Cardiovascular disease diagnostic and therapeutic targets
AU2002230848B2 (en) * 2000-12-14 2008-01-24 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2429528T3 (en) 2001-01-02 2013-11-15 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP4777602B2 (en) * 2001-01-26 2011-09-21 シェーリング コーポレイションSchering Corporation Combination of peroxisome proliferator activated receptor (PPAR) activator and sterol absorption inhibitor and treatment of vascular symptoms
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US20040071633A1 (en) * 2002-02-19 2004-04-15 Wright Samuel D. Method for determining efficacy of reverse cholesterol transport enhancing agents
CA2438899A1 (en) * 2001-02-21 2002-09-06 Samuel D. Wright Method for determining efficacy of reverse cholesterol transport enhancing agents
GB0108800D0 (en) 2001-04-07 2001-05-30 Glaxo Group Ltd Novel compounds
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
PT1429756E (en) * 2001-09-21 2007-01-31 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
CA2464531A1 (en) 2001-11-05 2003-05-15 Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
AT436017T (en) * 2001-11-09 2009-07-15 Medstar Res Inst METHOD FOR THE USE OF PHYSIOLOGICAL MARKERS FOR THE EVALUATION OF A HEART CIRCUIT RISK
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
EP1532108B1 (en) 2002-07-29 2016-06-29 Cardax Pharma, Inc. Astaxanthin esters for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
AU2003270909A1 (en) 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
AU2003291012A1 (en) * 2002-11-15 2004-06-15 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
US20050026168A1 (en) * 2002-12-13 2005-02-03 Genesis Group Inc. Method for the detection of risk factors associated with myocardial infarction
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
JP4589919B2 (en) * 2003-03-07 2010-12-01 シェーリング コーポレイションSchering Corporation Substituted azetidinone compounds, their formulations and uses for the treatment of hypercholesterolemia
JP5137228B2 (en) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
AT413944B (en) * 2003-05-27 2006-07-15 Binder Eva Dkfm Use of oxicam compounds
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
JP2007518062A (en) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド Method for diagnosing sepsis and composition for diagnosing
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
WO2005046675A2 (en) * 2003-11-07 2005-05-26 Jordan Holtzman Methods for enhancing glutathione peroxidase activity
DK1694342T3 (en) * 2003-11-12 2021-02-08 Univ Pennsylvania PROCEDURES FOR THE USE OF GELSOLIN FOR THE TREATMENT OR PREVENTION OF BACTERIAL SEPSIS
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2381551T3 (en) 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
WO2005055956A2 (en) * 2003-12-09 2005-06-23 Essential Skincare, Llc Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
WO2005078452A1 (en) * 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
WO2005083430A1 (en) * 2004-02-25 2005-09-09 Massachusetts Eye & Ear Infirmary Biomarkers for age-related macular degeneration (amd)
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2607686C (en) * 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
CA2567223A1 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
US9372190B2 (en) * 2004-05-26 2016-06-21 Region Nordjylland Method of evaluation of the relative risk of developing atherosclerosis in patients
WO2005121758A1 (en) * 2004-06-03 2005-12-22 Ciphergen Biosystems, Inc. Biomarkers for peripheral artery disease
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US20060020043A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for reducing C-reactive protein
WO2006020498A2 (en) 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
DE102004042530B4 (en) * 2004-09-02 2006-10-19 Mosaiques Diagnostics And Therapeutics Ag Method for the diagnosis of arteriosclerosis
WO2006031592A1 (en) * 2004-09-09 2006-03-23 University Of Massachusetts Disease markers for early stage atherosclerosis
AU2005284830A1 (en) * 2004-09-13 2006-03-23 Lipomics Technologies, Inc. Metabolite markers for weight management
ES2439229T3 (en) * 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of systemic inflammation markers after treatment
JP2008522980A (en) * 2004-12-06 2008-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents of The University of California Methods for improving the structure and function of small blood vessels
PL1879599T3 (en) * 2005-04-20 2014-03-31 Hutchinson Fred Cancer Res Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
MX2007013430A (en) * 2005-04-29 2008-03-19 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response.
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
JP5041506B2 (en) * 2005-08-30 2012-10-03 株式会社バイオマーカーサイエンス Disease detection method, substance evaluation method, substance screening method, and use as a marker
US20090054515A1 (en) * 2006-02-14 2009-02-26 Pola Chemical Industries Inc. Skin-whitening cosmetic
WO2007106577A2 (en) * 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
KR101556790B1 (en) * 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. Use of gelsolin to diagnose and treat inflammatory diseases
PL2848938T3 (en) 2006-04-24 2018-02-28 Critical Care Diagnostics, Inc. Evaluating the efficacy of a treatment in a subject based on ST2 levels
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
CA2650963C (en) * 2006-05-01 2020-09-15 Critical Care Diagnostics, Inc. St2 as a cardiovascular disease marker for high-bmi or impaired renal function patients
US20100055683A1 (en) * 2006-05-02 2010-03-04 Critical Care Diagnostics, Inc. Diagnosis of pulmonary and/or cardiovascular disease
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008095492A2 (en) * 2007-02-05 2008-08-14 Aarhus Universitet A method for diagnosing atherosclerotic plaques by measurement of cd36
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2195331T3 (en) 2007-08-28 2014-02-03 Uab Research Foundation Synthetic polypeptids similaring apolipoprotein e and methods of use
US9086425B2 (en) * 2007-08-29 2015-07-21 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US9423405B2 (en) * 2007-12-05 2016-08-23 The Cleveland Clinic Foundation Trimethylamine compounds as risk predictors of cardiovascular disease
PL2250280T3 (en) * 2008-01-25 2015-06-30 Massachusetts Gen Hospital Therapeutic uses of gelsolin in renal failure
DK2269063T3 (en) 2008-04-18 2013-12-02 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
AU2009248057B2 (en) * 2008-05-13 2013-02-21 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
US20100105746A1 (en) * 2008-08-01 2010-04-29 Clary Clish Method for treating metabolic diseases
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
JP5379616B2 (en) 2009-09-09 2013-12-25 株式会社日立製作所 Marker factors and applications of atherosclerosis
CN102812359A (en) * 2009-11-13 2012-12-05 Bg医药公司 Risk Factors And Prediction Of Myocardial Infarction
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US8708906B1 (en) * 2011-09-07 2014-04-29 Allen J. Orehek Method for the prevention of dementia and Alzheimer's disease
SG11201501271TA (en) 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
AU2013360024B2 (en) * 2012-12-12 2019-02-28 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10328045B2 (en) 2014-09-12 2019-06-25 Children's Medical Center Corporation, Inc. Dietary emulsion formulations and methods for using the same
KR20170122145A (en) * 2016-04-26 2017-11-03 서울대학교산학협력단 A device for providing information using saliva
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Method for determining risks associated with cardiovascular diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4287202A (en) * 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
JPH0410446B2 (en) * 1983-12-27 1992-02-25
JPS625970A (en) * 1985-03-15 1987-01-12 Terumo Corp Pyrazine derivative and platelet coagulation inhibitor containing same
US4902630A (en) * 1985-07-22 1990-02-20 Abbott Laboratories Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5003065A (en) * 1988-06-14 1991-03-26 Carey Merritt Compounds and process for measuring c-reactive protein
US5500345A (en) * 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
US5272258A (en) * 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor

Also Published As

Publication number Publication date
EP1493439A1 (en) 2005-01-05
JP3805381B2 (en) 2006-08-02
JP2001525058A (en) 2001-12-04
PT1493439E (en) 2012-01-10
EP2305235A1 (en) 2011-04-06
EP1003501A4 (en) 2001-01-17
ES2374621T3 (en) 2012-02-20
AU7100898A (en) 1998-10-22
DE69829293T2 (en) 2006-04-13
US6040147A (en) 2000-03-21
PT1003501E (en) 2005-07-29
DE69829293D1 (en) 2005-04-14
CY1112261T1 (en) 2015-12-09
EP1003501A1 (en) 2000-05-31
ES2239801T3 (en) 2005-10-01
JP2015079003A (en) 2015-04-23
EP1003501B1 (en) 2005-03-09
JP2008120800A (en) 2008-05-29
JP2013036996A (en) 2013-02-21
AT530180T (en) 2011-11-15
EP1003501B9 (en) 2005-06-08
CA2285091A1 (en) 1998-10-08
DK1003501T3 (en) 2005-07-18
EP1493439B1 (en) 2011-10-26
DK1493439T3 (en) 2012-01-30
WO1998043630A1 (en) 1998-10-08
EP2305236A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
AT290375T (en) Use of a means to reduce the risk of cardiovascular diseases
DE69839259D1 (en) Arrangement of line to heart
AT205102T (en) An assembly to practice walking
AT442156T (en) Use of neuregulin to influence the heart muscular function
FR2727540B1 (en) Help to distribute the load of a distributed application
AT227309T (en) Analogs of the glucagon-like peptides -2
AT314471T (en) Human humological humological
AT223966T (en) Use of a fermenter
DK1007055T3 (en) Use of amifostine
AT239474T (en) Use of levobupivacain
DK0739227T3 (en) discus
AT180289T (en) Use of a connection
AT251209T (en) Use of fat derivatives as a grillanner
DE69820648D1 (en) walker
NL193091B (en) Can be attached to the outside of a building.
HK1039059A1 (en) Methods of downmodulating the immune response to therapeutic proteins
DE69811864T2 (en) Manufacture of tape-workpieces
DE69827343D1 (en) Use of ethyl 3-methyl-2-oxopnetanoate as a fragrance
AT168825T (en) Tableau lifted to the user
AT204355T (en) Use of a transparent component as a hard covering
ATA84297A (en) Cuff to cover turned parts
FR2770450B1 (en) Use of alcoxylated triglycerides
AT329044T (en) Gen, relating to mental diseases
BR7701894U (en) Constructive provision applied to the toy
BR7702513U (en) Constructive arrangement applied to a parasol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003501

Country of ref document: EP